Share on facebook
Share on pinterest
Share on twitter
Share on email
Share on whatsapp


Journal of Clinical Medicine, 2019

Iftach Sagy MD PhD1,2, Lihi Bar-Lev Schleider MA2,3, Mahmoud Abu-Shakra MD4 and Victor Novack MD PhD2

1Department of Rheumatology, Rabin Medical Center, Petach Tikva Israel; 2Cannabis Clinical Research Institute, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be’er-Sheva, Israel; 3Research Department, Tikun Olam LTD; 4Department of Rheumatology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be’er-Sheva, Israel

Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. 367 fibromyalgia patients participated in a prospective observational study with 6 months follow-up period. The aim of the study, conducted in collaboration with the Department of Rheumatology at Rabin Medical Center, was to investigate the characteristics, safety and effectiveness of medical cannabis therapy for fibromyalgia.

STUDY POPULATION: 367 fibromyalgia patients (301 females, mean age 52.9).

STUDY PRODUCT: Most patients consumed Alaska, Erez and Avidakel.


  • Only 28 patients (7.6%) discontinued treatment during six months of treatment.
  • Overall improvement – 81.1% of patients reported a moderate (at least) improvement in their condition with no serious side effects.
  • Decrease in pain intensity – the overall pain intensity decreased from a median of 9.0 before starting treatment to 5.0 after six months.
  • Decreased depression – 80.8% of patients reported improvement in depression‐related symptoms.
  • Improvement in sleep – 73.4% of patients reported improved sleep; 13.2% reported their sleep problems were fully relieved.
  • Improving quality of life – 61.9% of patients reported their quality of life to be “good or very good,” after half a year of active treatment, whereas only 2.7% of patients rated their quality of life at this level prior to beginning treatment.
  • Decrease in drug use – 22.2% of patients stopped or reduced their dosage of opioids; 20.3% reduced their dosage of benzodiazepines.
  • The most common side effects were mild and included dizziness (7.9%), dry mouth (6.7%) and gastrointestinal symptoms (5.4%).
  • Medical cannabis appears to be a safe and effective alternative for the treatment of fibromyalgia symptoms.


Have you liked our facebook page?

Common Questions

Ordering Tikun Olam Products

Proudly leading the revolution for modern Cannabis treatment

Related Topics

Treatment of Crohn’s Disease with Cannabis: An Observational Study IMAJ – The Israel Medical Association Journal, 2011 Timna Naftali 1, Lihi Bar Lev, Doron Yablecovitch,

Medical Cannabis in Parkinson Disease: Real-Life Patients’ ExperienceClinical Neuropharmacology, 2017 Yacov Balash1,2, Lihi Bar-Lev Schleider3, Amos D. Korczyn2, Herzel Shabtai1, Judith Knaani1, Alina Rosenberg4, Yehuda Baruch5, Ruth

Epidemiological Characteristics, Safety and Efficacy of Medical Cannabis in the Elderly European Journal of Internal Medicine, 2018 Ran Abuhasira1, Lihi Bar-Lev Schleider1,2, Raphael Mechoulam3, Victor

Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol 2019 Timna Naftali 1 2,